Market evolution: Immunological products (CN 300215) — 2015–2025

Introduction

This report analyses the trade dynamics of EU trade with non-EU countries in immunological products (Combined Nomenclature code 300215) over the 2017–2025 period, as provided by the available data window. The sector, encompassing therapeutic and prophylactic immunological preparations excluding diagnostics, exhibits remarkable growth, structural shifts, and notable volatility. The analysis identifies three dominant dynamics: the EU's transformation into a major net exporter, a fundamental reorientation of its trade partnerships, and the sector's exposure to significant supply shocks and price volatility, particularly around the period of the COVID-19 pandemic.

1. The Emergence of a Dominant Trade Surplus Driven by Exponential Export Growth

Over the period, the EU's trade position in immunological products underwent a radical transformation, moving from a modest surplus to a position of overwhelming export dominance. This shift was fueled primarily by an explosive growth in export values, which outpaced the growth in imports significantly.

1.1 A Trade Balance Surplus Expanded Over Twenty-Fold

The EU's trade balance in immunological products with the world surged from €1.64 billion in 2017 to €41.71 billion in 2025, an increase of over 2,442% (General Overview). This dramatic improvement was the direct result of export growth vastly exceeding import growth.

1.2 Export Growth Was Driven by Both Value and Price Increases

While the physical quantity of exports (in net tonnes) grew by 41.6%, the value per tonne (price) surged by 168.4%. This indicates that the EU's export boom was not merely a volume story but was heavily influenced by a shift towards higher-value products or significant price inflation within the sector.

• Export Quantity: Increased from 9,177 tonnes in 2017 to 12,992 tonnes in 2025.
• Export Price: Rose from €1.97 million per tonne in 2017 to €5.28 million per tonne in 2025.

1.3 Imports Grew More Modestly and Were More Volatile

Import values grew by 63.9% over the same period. However, import data shows high volatility, particularly in quantity and price, suggesting potential disruptions or irregular trade flows. The import price saw a minimum of €285,802 per tonne (2022) and a maximum of €5.40 million per tonne (2025), indicating extreme instability in average import unit values.

2. A Fundamental Reorientation of Trade Partners and Production Specialization

The growth in trade was accompanied by a significant reshaping of the EU's partnership landscape. The bloc's export relationships became more concentrated and targeted major economies, while import sources diversified. Internally, the EU's production of these goods became highly specialized in a handful of member states.

2.1 The United States Became the EU's Primary Export Market

The United States emerged as the overwhelmingly dominant destination for EU exports, with its share growing enormously. The value of exports to the US grew from €4.50 billion in 2017 to €36.78 billion in 2025, a 717% increase (Top partners by value).

2.2 Import Sources Diversified, with Switzerland Remaining the Largest Supplier

Switzerland remained the largest source of EU imports, with its value growing by 117% to €14.95 billion in 2025. Notably, imports from South Korea saw a massive, volatile spike, especially around 2022, while traditional partners like the United Kingdom and Japan saw declining shares. The category "Countries and territories not specified" saw a dramatic, anomalous increase.

2.3 Internal EU Production and Specialization Became Highly Concentrated

Production of immunological products within the EU is concentrated in a few member states with strong comparative advantages. In 2025, Ireland, Belgium, and the Netherlands were the most specialized producers, with Ireland showing a very high Revealed Symmetric Comparative Advantage (RSCA) of 0.82 (Most specialised reporters). This specialization is reflected in trade flows, where Germany, Ireland, and the Netherlands were the top EU exporters in 2025. EU production value (for the broader ProdCom category) grew from €29.2 billion to €48.2 billion between the first and last available periods, a 65% increase.

3. Pronounced Volatility, Structural Shocks, and Strategic Autonomy Considerations

The immunological products market exhibited high price volatility and was subject to severe supply shocks, particularly during the COVID-19 pandemic era. Despite this, the EU's position strengthened in terms of strategic autonomy, though export concentration increased.

3.1 Trade Was Marked by High Price Volatility and Severe Shocks

The data detects specific, severe shocks, with the most prominent occurring in 2022. An extreme price shock was identified for imports from South Korea in 2022, with a price abnormality score of 77.4 and a price shift of +1,163% (Top shock events). Export prices to Saudi Arabia and Brazil also showed significant abnormal spikes in the same year. These events align with the global disruption of pharmaceutical and biological supply chains during the pandemic.

3.2 The EU Strengthened its Net Exporter Position, Enhancing Strategic Autonomy

The EU's net import reliance metric became increasingly negative, moving from -165% in 2017 to -537% in 2025. A negative value signifies a net exporter position; this tripling of the negative figure indicates a substantial strengthening of the EU's self-sufficiency and its role as a global supplier in this sector. This reduces vulnerability to external supply disruptions for these specific immunological goods.

3.3 Export Concentration Increased, While Trade Intensity Slightly Decreased

Paradoxically, while strategic autonomy improved, the concentration of export markets increased. The Herfindahl-Hirschman Index (HHI) for export value more than doubled from 1,491 in 2017 to 3,126 in 2025 (Concentration HHI), indicating greater reliance on fewer export partners (primarily the US). Meanwhile, the overall trade intensity (exports + imports as a share of production) showed a slight decline, and export propensity (exports as a share of production) fell from 219% to 179%, suggesting that while exports grew, production grew at a relatively faster pace.

Conclusion

The EU market for immunological products (CN 300215) from 2017 to 2025 was characterized by explosive export-led growth, culminating in a massive and expanding trade surplus. This was fueled by soaring demand and prices, particularly from the United States, which became the EU's paramount export market. Internally, production and expertise became highly concentrated in a few specialized member states.

The period was also marked by significant turbulence, including extreme price volatility and a major supply shock in 2022, likely linked to the COVID-19 pandemic. Despite this volatility, the EU's strategic position fundamentally improved: it solidified its role as a major net global exporter, thereby enhancing its strategic autonomy for this category of goods. However, this came at the cost of increased export market concentration. The outlook suggests a sector of high importance, high growth, but also high exposure to geopolitical and public health dynamics in key partner markets.